If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials. OSA is a prevalent ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

The letter went to Xcel Peptides, SwissChems, Summit Research and Prime Peptides, four online companies it said were selling unapproved GLP-1 drugs, including semaglutide and tirzepatide.

Please provide your email address to receive an email when new articles are posted on . A post hoc analysis of the SURMOUNT-1 and SURMOUNT-2 trials found that early responders to tirzepatide, or ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...